Advertisement
UK markets open in 3 hours 11 minutes

  • NIKKEI 225

    38,329.39
    +777.23 (+2.07%)
     

  • HANG SENG

    17,095.09
    +266.16 (+1.58%)
     

  • CRUDE OIL

    83.41
    +0.05 (+0.06%)
     

  • GOLD FUTURES

    2,337.80
    -4.30 (-0.18%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,501.80
    +36.50 (+0.07%)
     

  • CMC Crypto 200

    1,434.14
    +19.38 (+1.37%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Guardant Health to Participate in Upcoming June Investor Conferences

Business Wire
·1-min read

PALO ALTO, Calif., May 26, 2023--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

  • William Blair 43rd Annual Growth Stock Conference in Chicago, IL
    Presentation on Tuesday, June 6th at 4:40 p.m. Central Time

  • Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA
    Fireside Chat on Monday, June 12th at 4:00 p.m. Pacific Time

Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.

ADVERTISEMENT

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005834/en/

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035